Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.

Abstract: The current invention provides high specificity monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, which can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for preventing, inhibiting, reducing, or treating chronic kidney disease, conditions leading to or arising from it, and/or negative effects of each thereof.

Abstract: The current invention provides high specificity mouse monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.

Abstract: The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.

Abstract: The present invention provides a lectin from Crenomytilus grayanus or Mytilus trossulus as diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated from Crenomytilus grayanus or RussiaSea-002 (also called as MTL) isolated from Mytilus trossulus.

Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma Atractylodis macrocephalae, Eucommiae cortex, Lonicerae caulis, and Hedyotidis diffusae Herba thereof for use in treating a subject afflicted with active nephritis.

Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: The present invention relates to a method for diagnosis of a chronic kidney disease in a subject by detecting the expression level of a sodium-glucose linked transporter 2 (SGLT2) protein in urine samples. A method for monitoring progression of a chronic kidney disease in a patient is also provided.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: The present invention relates to a method for treating inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of 2-methoxy-4-methylphenol or a pharmaceutically acceptable salt or a physiologically functional derivative thereof, wherein the compound is in a therapeutically effective amount to inhibit NO or IL-6 expression, caspase-1 activation or IL-1? secretion, and NLRP3 and IL-1? precursor expression in inflammatory cells of the subject.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment.

Abstract: A method for analyzing apoptosis inducing factor-2 (AIF-2) is disclosed, which has not been found in urine samples of human patients with chronic kidney disease, to establish AIF-2 as a non-invasive biomarker for chronic kidney disease. The method includes: collecting a plurality of urine samples; conducting western blot for each urine sample for detecting the AIF-2 protein content in each urine sample; and conducting statistical analysis of the AIF-2 protein content in each urine sample to establish AIF-2 as a biological marker for chronic kidney disease.

Abstract: The present invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of a composition comprising bamboo vinegar or the phenolic fraction thereof. The method for preparing the phenolic fraction is also provided.

Abstract: The preset invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of a composition comprising bamboo vinegar or the phenolic fraction thereof. The method for preparing the phenolic fraction is also provided.